Advertisement

Topics

Soligenix to initiate Phase III trial of SGX942 to treat HNC-associated oral mucositis

19:00 EDT 3 May 2017 | Net Resources International

Soligenix has obtained clearance from the US Food and Drug Administration (FDA) to initiate a Phase III clinical trial of SGX942 (dusquetide) to treat oral mucositis caused in head and neck cancer (HNC) patients who are receiving chemoradiation (CRT)…

Original Article: Soligenix to initiate Phase III trial of SGX942 to treat HNC-associated oral mucositis

NEXT ARTICLE

More From BioPortfolio on "Soligenix to initiate Phase III trial of SGX942 to treat HNC-associated oral mucositis"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...